FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche's Avastin
Roche now has another big biosimilar rival to contend with.
The FDA has OK’d Mvasi, a knockoff of a drug that earned $3 billion in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
